VASCULAR BIOGENICS LTD (VBLT)
IL0011327454 - Common Stock
Overall VBLT gets a fundamental rating of 3 out of 10. We evaluated VBLT against 587 industry peers in the Biotechnology industry. While VBLT seems to be doing ok healthwise, there are quite some concerns on its profitability. VBLT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year VBLT has reported negative net income.
VBLT had a negative operating cash flow in the past year.
In the past 5 years VBLT always reported negative net income.
VBLT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VBLT's Return On Assets of -64.74% is on the low side compared to the rest of the industry. VBLT is outperformed by 64.62% of its industry peers.
With a Return On Equity value of -82.94%, VBLT perfoms like the industry average, outperforming 46.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.74% | ||
| ROE | -82.94% | ||
| ROIC | N/A |
ROA(3y)-71.09%
ROA(5y)-57.33%
ROE(3y)-93.2%
ROE(5y)-74.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VBLT's Gross Margin of 96.47% is amongst the best of the industry. VBLT outperforms 97.01% of its industry peers.
VBLT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VBLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.51%
GM growth 5Y-2.9%
2. Health
2.1 Basic Checks
VBLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VBLT has been increased compared to 1 year ago.
The number of shares outstanding for VBLT has been increased compared to 5 years ago.
There is no outstanding debt for VBLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VBLT has an Altman-Z score of -16.80. This is a bad value and indicates that VBLT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.80, VBLT is not doing good in the industry: 87.54% of the companies in the same industry are doing better.
There is no outstanding debt for VBLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.8 |
ROIC/WACCN/A
WACC8.55%
2.3 Liquidity
A Current Ratio of 4.63 indicates that VBLT has no problem at all paying its short term obligations.
VBLT has a Current ratio of 4.63. This is comparable to the rest of the industry: VBLT outperforms 44.19% of its industry peers.
A Quick Ratio of 4.63 indicates that VBLT has no problem at all paying its short term obligations.
VBLT's Quick ratio of 4.63 is in line compared to the rest of the industry. VBLT outperforms 45.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.63 |
3. Growth
3.1 Past
VBLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.41%, which is quite impressive.
VBLT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.91%.
The Revenue for VBLT have been decreasing by -45.64% on average. This is quite bad
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q90.85%
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y-45.64%
Revenue growth Q2Q-100%
3.2 Future
Based on estimates for the next years, VBLT will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.84% on average per year.
Based on estimates for the next years, VBLT will show a very strong growth in Revenue. The Revenue will grow by 29.94% on average per year.
EPS Next Y-15.38%
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
EPS Next 5Y-11.84%
Revenue Next Year68.85%
Revenue Next 2Y29.94%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VBLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VBLT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as VBLT's earnings are expected to decrease with -15.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
5. Dividend
5.1 Amount
No dividends for VBLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VASCULAR BIOGENICS LTD
NASDAQ:VBLT (10/16/2023, 7:02:23 PM)
After market: 0.168 +0.01 (+7.69%)0.156
-0.02 (-8.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.11M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.74% | ||
| ROE | -82.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.47% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.63 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-15.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y